SE0102036D0 - Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof - Google Patents

Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof

Info

Publication number
SE0102036D0
SE0102036D0 SE0102036A SE0102036A SE0102036D0 SE 0102036 D0 SE0102036 D0 SE 0102036D0 SE 0102036 A SE0102036 A SE 0102036A SE 0102036 A SE0102036 A SE 0102036A SE 0102036 D0 SE0102036 D0 SE 0102036D0
Authority
SE
Sweden
Prior art keywords
norapomorphine
apomorphine
pro
drugs
propyl
Prior art date
Application number
SE0102036A
Other languages
English (en)
Inventor
Haakan Vilhelm Wikstroem
Durk Dijkstra
Thomas Ivo Franchiscus Cremers
Original Assignee
Axon Biochemicals Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Biochemicals Bv filed Critical Axon Biochemicals Bv
Priority to SE0102036A priority Critical patent/SE0102036D0/sv
Publication of SE0102036D0 publication Critical patent/SE0102036D0/sv
Priority to IL15889802A priority patent/IL158898A0/xx
Priority to PCT/SE2002/001106 priority patent/WO2002100377A1/en
Priority to NZ529623A priority patent/NZ529623A/en
Priority to EP02736413A priority patent/EP1401398A1/en
Priority to EA200400007A priority patent/EA008409B1/ru
Priority to JP2003503201A priority patent/JP2005508865A/ja
Priority to KR10-2003-7015814A priority patent/KR20040007644A/ko
Priority to KR1020097015053A priority patent/KR20090085162A/ko
Priority to PL02367883A priority patent/PL367883A1/xx
Priority to BR0210261-7A priority patent/BR0210261A/pt
Priority to US10/478,692 priority patent/US20040220205A1/en
Priority to HU0400200A priority patent/HUP0400200A3/hu
Priority to CA002449571A priority patent/CA2449571A1/en
Priority to MXPA03011314A priority patent/MXPA03011314A/es
Priority to CZ20033332A priority patent/CZ20033332A3/cs
Priority to AU2002309429A priority patent/AU2002309429B2/en
Priority to CNB028114760A priority patent/CN1286451C/zh
Priority to ZA200309048A priority patent/ZA200309048B/en
Priority to NO20035438A priority patent/NO20035438L/no
Priority to US12/033,646 priority patent/US20080145417A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE0102036A 2000-08-17 2001-06-08 Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof SE0102036D0 (sv)

Priority Applications (21)

Application Number Priority Date Filing Date Title
SE0102036A SE0102036D0 (sv) 2001-06-08 2001-06-08 Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
CNB028114760A CN1286451C (zh) 2001-06-08 2002-06-07 用于有效施用阿扑***、6аR－(－)－N－丙基－去甲阿扑***和它们的衍生物及其前药的药物制剂
KR1020097015053A KR20090085162A (ko) 2001-06-08 2002-06-07 아포모르핀, 6ａＲ-(-)-Ｎ-프로필-노르아포모르핀 및 이들의 유도체 및 이들의 프로드럭을 효과적으로 투여하기 위한 약학 조제물
BR0210261-7A BR0210261A (pt) 2001-06-08 2002-06-07 Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes
NZ529623A NZ529623A (en) 2001-06-08 2002-06-07 Pharmaceutical formulation for intraduodenal administration of apomorphine, 6aR-(-)-N-propyl-norapomorphine and their derivatives and pro-drugs thereof
EP02736413A EP1401398A1 (en) 2001-06-08 2002-06-07 PHARMACEUTICAL FORMULATION FOR THE EFFICIENT ADMINISTRATION OF APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND THEIR DERIVATIVES AND PRO-DRUGS THEREOF
EA200400007A EA008409B1 (ru) 2001-06-08 2002-06-07 ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ
JP2003503201A JP2005508865A (ja) 2001-06-08 2002-06-07 アポモルフィン、６ａＲ−（−）−Ｎ−プロピル−ノルアポモルフィンおよびそれらの誘導体、並びにそれらのプロドラッグを効率的に投与するための薬学的処方剤
KR10-2003-7015814A KR20040007644A (ko) 2001-06-08 2002-06-07 아포모르핀, 6ａＲ-(-)-Ｎ-프로필-노르아포모르핀 및이들의 유도체 및 이들의 프로드럭을 효과적으로 투여하기위한 약학 조제물
IL15889802A IL158898A0 (en) 2001-06-08 2002-06-07 PHARMACEUTICAL COMPOSITIONS CONTAINING APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND DERIVATIVES THEREOF
PL02367883A PL367883A1 (en) 2001-06-08 2002-06-07 Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
PCT/SE2002/001106 WO2002100377A1 (en) 2001-06-08 2002-06-07 PHARMACEUTICAL FORMULATION FOR THE EFFICIENT ADMINISTRATION OF APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND THEIR DERIVATIVES AND PRO-DRUGS THEREOF
US10/478,692 US20040220205A1 (en) 2001-06-08 2002-06-07 Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
HU0400200A HUP0400200A3 (en) 2001-06-08 2002-06-07 Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
CA002449571A CA2449571A1 (en) 2001-06-08 2002-06-07 Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
MXPA03011314A MXPA03011314A (es) 2001-06-08 2002-06-07 Formulacion farmaceutica para la administracion eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina y sus derivados y pro-farmacos de los mismos.
CZ20033332A CZ20033332A3 (cs) 2001-06-08 2002-06-07 Farmaceutická formulace pro účinné podání apomorfinu, 6aR-(-)-N-propyl-norapomorphine a jeho derivátů a jeho proléčiv
AU2002309429A AU2002309429B2 (en) 2000-08-17 2002-06-07 Pharmaceutical formulation for the efficient administration of apomorphine, 6aR-(-)-N-propyl-norapomorphine and their derivatives and pro-drugs thereof
ZA200309048A ZA200309048B (en) 2001-06-08 2003-11-20 Pharmaceutical formulation for the efficient administration of apomorphine, 6aR-(-)-N-propyl-norapomorphine and their derivatives and pro-drugs thereof.
NO20035438A NO20035438L (no) 2001-06-08 2003-12-05 Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav
US12/033,646 US20080145417A1 (en) 2001-06-08 2008-02-19 Pharmaceutical formulation for the efficient administration apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102036A SE0102036D0 (sv) 2001-06-08 2001-06-08 Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof

Publications (1)

Publication Number Publication Date
SE0102036D0 true SE0102036D0 (sv) 2001-06-08

Family

ID=20284413

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0102036A SE0102036D0 (sv) 2000-08-17 2001-06-08 Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof

Country Status (19)

Country Link
US (2) US20040220205A1 (sv)
EP (1) EP1401398A1 (sv)
JP (1) JP2005508865A (sv)
KR (2) KR20090085162A (sv)
CN (1) CN1286451C (sv)
AU (1) AU2002309429B2 (sv)
BR (1) BR0210261A (sv)
CA (1) CA2449571A1 (sv)
CZ (1) CZ20033332A3 (sv)
EA (1) EA008409B1 (sv)
HU (1) HUP0400200A3 (sv)
IL (1) IL158898A0 (sv)
MX (1) MXPA03011314A (sv)
NO (1) NO20035438L (sv)
NZ (1) NZ529623A (sv)
PL (1) PL367883A1 (sv)
SE (1) SE0102036D0 (sv)
WO (1) WO2002100377A1 (sv)
ZA (1) ZA200309048B (sv)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
EP1644004A4 (en) 2003-06-20 2010-10-06 Ronald Aung-Din LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS
TWI404702B (zh) 2007-08-31 2013-08-11 Lundbeck & Co As H 兒茶酚胺衍生物和其前藥
US8129530B2 (en) 2007-08-31 2012-03-06 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
WO2010005507A1 (en) * 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
WO2010097087A1 (en) 2009-02-25 2010-09-02 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
PT2952191T (pt) 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
AU2011343429B2 (en) 2010-12-16 2016-10-20 Sunovion Pharmaceuticals Inc. Sublingual films
KR101374500B1 (ko) * 2012-10-09 2014-03-13 울산대학교 산학협력단 Ｒ(-)-프로필노르아포모르핀을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
US20170368052A1 (en) * 2014-12-23 2017-12-28 Neuroderm, Ltd. Crystal forms of apomorphine and uses thereof
BR112017018944A2 (pt) 2015-03-02 2018-05-15 Afgin Pharma Llc método de tratamento de um estado ou condição de doença em humanos com um medicamento carbinóide, e, método de tratamento de um estado ou condição de doença em um mamífero diferente de um humano com medicamento(s) carbinóide(s)
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
CA3127926A1 (en) 2015-04-21 2016-10-27 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
US20180280465A1 (en) 2015-09-28 2018-10-04 Ever Neuro Pharma Gmbh Aqueous composition of apomorphine for subcutaneous administration
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
CR20200225A (es) 2017-11-24 2020-07-25 H Lundbeck As Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
WO2020234274A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
CN113727974A (zh) 2019-05-21 2021-11-30 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
JP2022533311A (ja) 2019-05-21 2022-07-22 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
EP3972600A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
JP2023552699A (ja) 2020-11-17 2023-12-19 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
WO2023242355A1 (en) 2022-06-15 2023-12-21 Ever Neuro Pharma Gmbh Apomorphine prodrugs and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080456A (en) * 1971-10-26 1978-03-21 Schering Aktiengesellschaft Diacylapomorphines
DE2717001C2 (de) * 1977-04-18 1984-06-20 Karl O. Helm Ag, 2000 Hamburg Arzneimittel mit antithrombotischer Wirkung
US4120860A (en) * 1977-05-10 1978-10-17 Cooper Lab 3-Aryl-1-(2- or 4-iminodihydro-1-pyridyl)-2-propanol antiarrhythmic compounds
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US5222236A (en) * 1988-04-29 1993-06-22 Overdrive Systems, Inc. Multiple integrated document assembly data processing system
CA2013485C (en) * 1990-03-06 1997-04-22 John Michael Gardlik Solid consumer product compositions containing small particle cyclodextrin complexes
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
GB9700878D0 (en) * 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US6403605B1 (en) * 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
AU2001255818A1 (en) * 2000-04-07 2001-10-23 Tap Pharmaceutical Products Inc. Apomorphine derivatives and methods for their use
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
ATE421518T1 (de) * 2005-02-10 2009-02-15 Bristol Myers Squibb Co Dihydrochinazolinone als 5ht-modulatoren

Also Published As

Publication number Publication date
EA200400007A1 (ru) 2004-04-29
MXPA03011314A (es) 2004-12-06
PL367883A1 (en) 2005-03-07
HUP0400200A3 (en) 2008-03-28
NZ529623A (en) 2008-04-30
EP1401398A1 (en) 2004-03-31
CZ20033332A3 (cs) 2004-12-15
BR0210261A (pt) 2004-07-20
JP2005508865A (ja) 2005-04-07
CN1531420A (zh) 2004-09-22
IL158898A0 (en) 2004-05-12
KR20090085162A (ko) 2009-08-06
NO20035438L (no) 2004-02-05
CA2449571A1 (en) 2002-12-19
CN1286451C (zh) 2006-11-29
ZA200309048B (en) 2004-11-22
HUP0400200A2 (hu) 2004-06-28
US20040220205A1 (en) 2004-11-04
US20080145417A1 (en) 2008-06-19
AU2002309429B2 (en) 2007-08-09
NO20035438D0 (no) 2003-12-05
EA008409B1 (ru) 2007-04-27
KR20040007644A (ko) 2004-01-24
WO2002100377A1 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
SE0102036D0 (sv) Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
NO20025621D0 (no) Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser
AP1818A (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
BG104877A (en) N-substituted anminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
NZ516782A (en) Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
CY1117470T1 (el) Στερεα δοσολογικα σκευασματα με βελτιωμενη ενδοστοματικη προσροφηση
MXPA03005464A (es) Agentes antivirales.
UA84266C2 (uk) Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
HK1085667A1 (en) Non-nucleoside reverse transcriptase inhibitors
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
MY140398A (en) 4-AMINO-6-PHENYL-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES
WO2001032632A3 (en) Pharmaceutically active 4-substituted pyrimidine derivatives
ATE386725T1 (de) Heterocyclylverbindungen
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
GEP20084300B (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
SE0002934D0 (sv) New aporphine esters and in their use in therapy
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
SE0102440D0 (sv) New compound
SE9902935D0 (sv) Pharmaceutical compositions
SE9903995D0 (sv) New combination
CA2135179A1 (en) Pharmaceutical Compositions of Alkylsulphonamides 5HT1 Agonists for Rectal Administration
SE0001916D0 (sv) Novel formulation
BR0114395A (pt) Composição farmacêutica para administração por suprimento via oral
WO2002024661A3 (en) New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors